List of Excipients in Branded Drug MOMETASONE FUROATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	MOMETASONE FUROATE MONOHYDRATE	mometasone furoate monohydrate	0781-6355	BENZALKONIUM CHLORIDE
Sandoz Inc	MOMETASONE FUROATE MONOHYDRATE	mometasone furoate monohydrate	0781-6355	CARBOXYMETHYLCELLULOSE SODIUM
Sandoz Inc	MOMETASONE FUROATE MONOHYDRATE	mometasone furoate monohydrate	0781-6355	CELLULOSE, MICROCRYSTALLINE
Sandoz Inc	MOMETASONE FUROATE MONOHYDRATE	mometasone furoate monohydrate	0781-6355	CITRIC ACID MONOHYDRATE

Generic Drugs Containing MOMETASONE FUROATE

Company	Ingredient	NDC	Excipient
E Fougera & Co a division of Fougera Pharmaceuticals Inc	mometasone furoate	0168-0270	ALUMINUM STARCH OCTENYLSUCCINATE
E Fougera & Co a division of Fougera Pharmaceuticals Inc	mometasone furoate	0168-0270	HEXYLENE GLYCOL
E Fougera & Co a division of Fougera Pharmaceuticals Inc	mometasone furoate	0168-0270	PETROLATUM
E Fougera & Co a division of Fougera Pharmaceuticals Inc	mometasone furoate	0168-0270	PHOSPHORIC ACID

What are the Most Frequently-Used Excipients in MOMETASONE FUROATE?

# Of NDCs	Excipient
25	ALUMINUM STARCH OCTENYLSUCCINATE
5	BENZALKONIUM CHLORIDE
5	CARBOXYMETHYLCELLULOSE SODIUM
5	CELLULOSE, MICROCRYSTALLINE

Mometasone Furoate Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Mometasone furoate is a mature corticosteroid with commercial opportunity concentrated in formulation redesign, device performance, combination products, preservative reduction, and differentiated delivery systems. The active ingredient is used in nasal, inhaled, topical, and fixed-dose combination products. Core molecule exclusivity is no longer the principal barrier for most products; regulatory equivalence, device integration, formulation performance, manufacturing scale, and brand access are more important.

What dosage forms contain mometasone furoate?

Mometasone furoate is commercially used in four major dosage-form categories.

Dosage form	Representative product	Primary indication	Key formulation issue
Nasal spray suspension	Nasonex and authorized generics	Allergic rhinitis, nasal polyps	Particle size, suspension stability, spray pattern, preservative system
Dry-powder inhaler	Asmanex Twisthaler	Asthma maintenance	Lactose carrier, aerodynamic particle size, dose uniformity
Pressurized metered-dose inhaler	Asmanex HFA; Dulera combination	Asthma maintenance	Propellant compatibility, suspension stability, valve and actuator performance
Topical semisolid	Elocon and generics	Inflammatory dermatoses	Vehicle selection, skin penetration, sensory profile, preservative system

Mometasone furoate is highly potent and poorly water-soluble. That profile favors suspension-based delivery, micronization, particle engineering, and topical vehicles rather than conventional aqueous solutions.

Which excipients are used in mometasone furoate products?

The excipient system varies materially by route of administration.

Nasal spray excipients

Nasonex nasal spray contains mometasone furoate monohydrate in an aqueous suspension. The labeled excipients include microcrystalline cellulose and carboxymethylcellulose sodium, glycerin, sodium citrate, citric acid, polysorbate 80, benzalkonium chloride, phenethyl alcohol, and purified water, with pH adjustment as applicable.[1]

The excipient functions are distinct:

• Microcrystalline cellulose and carboxymethylcellulose sodium provide suspension structure and reduce settling.
• Glycerin adjusts tonicity and contributes to moisture retention.
• Polysorbate 80 improves wetting and dispersion of the hydrophobic drug.
• Sodium citrate and citric acid provide buffering.
• Benzalkonium chloride and phenethyl alcohol support antimicrobial preservation.
• Water is the continuous phase.

This architecture is commercially defensible only when it produces a reproducible spray plume, droplet-size distribution, delivered dose, and particle-size profile. An excipient substitution that preserves assay but changes nasal deposition can create regulatory and clinical problems.

Dry-powder inhaler excipients

Asmanex Twisthaler uses lactose monohydrate as the carrier excipient. The lactose contains small quantities of milk proteins, which is relevant to labeling and patient screening.[2]

For a lactose-based dry-powder inhaler, the main formulation variables are:

• Lactose particle-size distribution.
• Fine lactose fraction.
• Drug-to-carrier ratio.
• Surface energy and adhesion between drug and carrier.
• Moisture content.
• Device resistance and airflow dependence.
• Delivered-dose and fine-particle-dose consistency.

Mometasone furoate must be micronized and distributed across the carrier in a way that allows detachment during inhalation. The excipient is therefore linked to device performance. A generic manufacturer cannot assume that a visually similar lactose grade will deliver an equivalent aerosol.

Pressurized inhaler excipients

Asmanex HFA and Dulera use hydrofluoroalkane propellant systems. Dulera contains mometasone furoate and formoterol fumarate in a metered-dose inhaler. The formulation includes HFA-227, ethanol, and oleic acid, according to the product labeling.[3]

In this category, ethanol can improve drug wetting and suspension behavior, while oleic acid can modify particle interaction and suspension stability. The commercial formulation challenge is to control:

• Suspension flocculation.
• Valve retention.
• Drug sedimentation or creaming.
• Actuator deposition.
• Delivered dose across canister life.
• Compatibility with elastomers, coatings, and container materials.

The transition from legacy chlorofluorocarbon systems to hydrofluoroalkanes also creates lifecycle opportunities. Low-global-warming-potential propellant systems may support future reformulation programs, although the reformulation must preserve aerodynamic performance and clinical dose delivery.

Topical cream, ointment, and lotion excipients

Mometasone furoate topical products use different vehicles for different commercial objectives. Cream systems may contain water, propylene glycol, fatty alcohols, stearyl alcohol, cetearyl alcohol, glycols, surfactants, preservatives, and pH adjusters. Ointments generally use petrolatum-based or mineral-oil-based systems. Lotions may use water-rich emulsions with volatile or spreading components.[4]

For topical products, the vehicle controls:

• Drug release from the formulation.
• Partitioning into the stratum corneum.
• Skin hydration.
• Occlusivity.
• Spreadability.
• Residue and greasiness.
• Washability.
• Microbial preservation.

The strongest commercial opportunity is often a vehicle that improves adherence without changing the labeled corticosteroid strength. Foam, lotion, spray, and low-residue cream formats can target scalp, intertriginous, hairy, or cosmetically sensitive areas where ointments have poor patient acceptance.

How should an excipient strategy be designed for mometasone furoate?

A successful strategy should begin with the delivery route, not with a preferred excipient.

Nasal products

A nasal formulation program should prioritize:

1. Preservative-free or reduced-preservative delivery.
2. Stable suspension behavior over the labeled shelf life.
3. Low throat runoff and controlled nasal deposition.
4. Consistent actuation force and spray pattern.
5. Compatibility with multidose pump systems.
6. Reduced local irritation.

Potential excipient directions include alternative suspending polymers, nonionic surfactant systems, citrate or phosphate buffering, and unit-dose packaging that eliminates the need for antimicrobial preservatives. A preservative-free product can command a premium if it demonstrates patient or prescriber value, particularly in chronic use.

The formulation must avoid excessive viscosity. A thicker suspension can improve physical stability but may increase actuator force, alter plume geometry, and impair dose delivery.

Dry-powder inhalers

For inhaled mometasone furoate, the principal opportunity is to move beyond conventional lactose-carrier systems. Options include:

• Engineered lactose with controlled fines.
• Mannitol or alternative carbohydrate carriers.
• Spray-dried particles.
• Carrier-free porous particles.
• Coated carrier particles.
• Device-specific powder blends.

Carrier-free systems can reduce dependence on lactose variability and may support lower inhalation resistance. They can also create stronger intellectual-property positions through particle morphology, surface treatment, and device integration.

The major risk is regulatory comparability. Changes in emitted dose, fine-particle mass, plume or aerosol behavior, and regional lung deposition can complicate an abbreviated development path. A novel powder platform may require a 505(b)(2) strategy rather than a conventional ANDA, depending on the reference product and the extent of formulation and device change.[5]

Pressurized metered-dose inhalers

A propellant reformulation creates a substantial lifecycle opportunity. Development priorities include:

• HFA or next-generation low-global-warming propellant selection.
• Ethanol concentration.
• Oleic-acid or alternative surfactant concentration.
• Suspension settling rate.
• Valve and actuator compatibility.
• Dose uniformity at the beginning, middle, and end of canister life.

The strongest commercial position may come from a complete formulation-device system rather than from an excipient alone. Regulatory value rises when the new system provides an equivalent clinical dose with improved environmental performance, a smaller actuator, better plume characteristics, or more consistent patient use.

Topical products

Topical opportunities can be divided into three segments.

Segment	Formulation strategy	Commercial rationale
High-adherence daily therapy	Light cream, lotion, gel, or foam	Better cosmetic acceptability
Difficult anatomical sites	Scalp spray, solution, or low-residue lotion	Improved application to hair-bearing areas
Barrier-compromised skin	Emulsion with humectant and barrier-supportive excipients	Reduced irritation and improved moisturization
Premium dermatology	Novel vehicle or controlled-release system	Differentiation from generic creams and ointments

A topical reformulation must balance increased penetration against corticosteroid safety. Higher flux can improve efficacy but may increase local atrophy, telangiectasia, or systemic absorption. The commercial goal is usually improved usability and consistent application, not maximum penetration.

What commercial opportunities exist for mometasone furoate excipients?

Preservative-free nasal spray

A preservative-free nasal suspension is one of the clearest opportunities. It can target patients with chronic exposure concerns, nasal irritation, or sensitivity to benzalkonium chloride. Unit-dose packaging raises manufacturing and packaging costs, but it can support premium pricing and institutional positioning.

Excipient-enabled inhaler reformulation

A new carrier or propellant system can extend the commercial life of inhaled mometasone products. The opportunity is strongest where the formulation change is paired with:

• A lower-environmental-impact propellant.
• A smaller or easier-to-use inhaler.
• Lower inhalation resistance.
• Improved dose consistency.
• A fixed-dose combination with a long-acting bronchodilator.

Dulera demonstrates the value of combining mometasone furoate with formoterol fumarate. Similar lifecycle approaches can use different bronchodilators, although regulatory and clinical requirements will be product-specific.[3]

Premium topical vehicles

Mometasone furoate is well positioned for differentiated dermatology products because the active ingredient is potent and used at low concentrations. A manufacturer can pursue commercial separation through:

• Foam delivery.
• Scalp spray.
• Non-greasy lotion.
• Fast-drying solution.
• Barrier-supportive emulsion.
• Fragrance-free and low-irritant systems.
• Packaging designed for precise dosing.

The formulation must provide a credible patient benefit. A cosmetic change alone may not justify a premium after generic entry.

Pediatric and geriatric usability

Excipient and package design can target patients who have difficulty actuating nasal pumps, generating inhalation force, or spreading ointments. Commercial opportunities include:

• Lower-force nasal actuators.
• Breath-actuated or simplified inhalers.
• Metered topical pumps.
• Unit-dose topical packaging.
• Clearer dose markers.
• Reduced residue and improved washability.

These opportunities may be protected through device patents, human-factors data, trademarks, and trade secrets even when the active-ingredient patent estate is mature.

What patents protect mometasone furoate formulations?

The original composition-of-matter and product-specific patent protection for mometasone furoate has largely matured in major markets. Current protection is more likely to involve:

• Formulation composition.
• Particle-size distribution.
• Suspension stabilizers.
• Device architecture.
• Actuator geometry.
• Combination products.
• Manufacturing processes.
• Treatment methods.
• Specific strength and dosage-form configurations.

Nasonex, Asmanex, Dulera, and topical mometasone products have different regulatory and patent profiles. Orange Book-listed patents for approved drug products must be reviewed by product and strength because patents can cover the drug substance, formulation, method of use, or delivery device.[6]

For a new excipient platform, the strongest patent claims generally combine the excipient with measurable performance parameters. Examples include:

• A defined drug particle-size distribution.
• A specified fine-particle fraction.
• A suspension with a defined settling or redispersibility profile.
• A nasal spray with a defined droplet-size distribution.
• A topical vehicle with a defined release rate.
• A propellant formulation with defined valve-delivery characteristics.

Broad claims to common excipients are difficult to defend. Narrow claims tied to performance, process conditions, and device interaction are more commercially credible.

When does mometasone furoate lose exclusivity?

Mometasone furoate has already lost broad small-molecule exclusivity in several dosage-form categories. Generic competition is established for topical and nasal products, while inhaled products face greater technical barriers because of device and aerosol-equivalence requirements.

Product category	Exclusivity position	Main competitive barrier
Topical mometasone	Mature generic market	Vehicle equivalence and dermatology substitution
Nasal suspension	Generic competition established	Spray-equivalence testing and device performance
Dry-powder inhaler	More limited competition than topical products	Powder engineering and inhaler equivalence
HFA inhaler	Higher development complexity	Propellant, valve, actuator, and aerosol performance
Fixed-dose combination	Product-specific	Combination equivalence and device requirements

FDA regulatory exclusivity must be assessed separately from patent expiration. New chemical-entity exclusivity for mometasone furoate is not the current commercial driver. Any remaining value is more likely to arise from product-specific patents, pediatric exclusivity, formulation innovation, or device protection.[6][7]

What is the FDA regulatory status of mometasone furoate?

Mometasone furoate is an FDA-approved corticosteroid used in multiple routes of administration. FDA-approved products include nasal spray, inhaled products, fixed-dose inhaled combinations, and topical formulations.[1-4]

The regulatory pathway depends on the proposed product:

• A conventional generic topical product may use an ANDA if it meets equivalence requirements.
• A generic nasal spray must demonstrate pharmaceutical equivalence and device-related performance.
• An inhaled product may require extensive comparative aerodynamic and performance testing.
• A novel excipient, new device, or materially different delivery system may require a 505(b)(2) application.
• A new fixed-dose combination requires combination-product evidence and product-specific regulatory support.

The FDA Inactive Ingredient Database is important for excipient selection because prior use can support regulatory acceptability, while a new route, concentration, or exposure level may require additional justification.[8]

Which companies compete in mometasone furoate?

Competition includes originator companies, generic manufacturers, contract development organizations, device suppliers, and specialty dermatology companies.

Competitive group	Typical focus
Organon and legacy Schering-Plough/Merck assets	Nasonex and related commercial rights
Organon and legacy Merck respiratory assets	Asmanex and Dulera portfolios
Generic manufacturers	Nasal sprays, topical creams, ointments, and lotions
Specialty respiratory companies	Device-enabled inhaled products
Dermatology companies	Premium topical vehicles and packaging
CDMOs and excipient suppliers	Micronization, spray drying, suspension systems, and semisolids

Commercial ownership can vary by country and product. Licensing, distribution, and regional rights should be checked against current regulatory databases and corporate transaction records before valuation.

How strong is the patent estate for a new mometasone formulation?

A new mometasone formulation can have a moderate to strong patent position if it combines three elements:

1. A technically difficult formulation.
2. A measurable performance advantage.
3. A delivery device or manufacturing process that is difficult to design around.

The strongest positions are likely to arise in inhaled delivery, where the formulation and device operate as an integrated system. Nasal and topical products can also be protected, but generic design-around risk is higher because multiple excipient and package configurations may produce acceptable performance.

A practical freedom-to-operate review should examine:

• Active-ingredient patents.
• Formulation patents.
• Device patents.
• Method-of-use patents.
• Orange Book listings.
• Paragraph IV certifications.
• Patent litigation.
• Settlement agreements.
• Regulatory exclusivity.
• Trade secrets covering particle engineering and process control.

What generic launch risks exist for mometasone furoate?

Generic launch risk depends on the dosage form.

Topical products

The risk is high because multiple manufacturers can develop creams, ointments, and lotions. Brand defense depends on vehicle differentiation, prescriber loyalty, channel access, and any remaining formulation claims.

Nasal sprays

The risk is moderate. Generic development is more complex than a cream because the applicant must match suspension, spray, and device performance. Once several approved generics exist, price erosion can be substantial.

Inhaled products

The risk is lower in the near term but can be economically significant when a technically successful generic enters. Device complexity, formulation development, and FDA review can delay entry. Patent litigation and Paragraph IV certifications may influence the timing of launch.[6]

Biosimilar risk is not relevant. Mometasone furoate is a small molecule, not a biologic. Competition proceeds through generic and 505(b)(2) pathways rather than biosimilar approval.

What licensing deals could create value?

Licensing opportunities are most credible in four areas:

• Novel inhaler devices that can accommodate mometasone furoate.
• Low-global-warming propellant platforms.
• Carrier-free or engineered-particle dry powders.
• Premium topical vehicles with dermatology data.

A deal structure may include an upfront payment, development milestones, regulatory milestones, and royalties on net sales. The licensor’s value increases when it owns both formulation claims and device claims. An excipient supplier with only a commodity ingredient has weaker negotiating leverage than a supplier with a proprietary grade, manufacturing process, clinical evidence, and regulatory history.

What manufacturing and IP barriers matter most?

The highest barriers are process-specific rather than chemical.

Nasal suspension manufacturing

Critical capabilities include micronization, wetting, homogenization, aseptic or controlled microbial manufacturing, multidose pump filling, and spray-performance testing.

Inhaled products

Critical capabilities include micronized active manufacture, carrier blending, powder segregation control, canister and valve filling, actuator assembly, and aerodynamic particle-size testing.

Topical products

Critical capabilities include particle dispersion, emulsion control, scale-up of rheology, preservative effectiveness, tube or pump filling, and consistent drug release.

Trade secrets can protect mixing order, shear conditions, temperature control, milling parameters, and filling processes. These protections are valuable where patent claims are narrow or easy to design around.

Key Takeaways

• Mometasone furoate is a mature small-molecule corticosteroid with continuing value in differentiated delivery.
• The strongest excipient opportunities are preservative-free nasal systems, engineered inhalation powders, next-generation propellant formulations, and premium topical vehicles.
• Lactose remains important in dry-powder inhalers, while ethanol, oleic acid, and HFA propellants are central to metered-dose systems.
• Generic risk is highest for topical products, moderate for nasal sprays, and more technically constrained for inhaled products.
• Biosimilar competition does not apply.
• New commercial value should be built around measurable delivery performance, device integration, patient usability, and manufacturing know-how.
• Formulation and device patents are more commercially relevant than legacy composition-of-matter protection.
• A 505(b)(2) pathway may be appropriate for materially novel excipient, device, or delivery systems.

FAQs

Can mometasone furoate be formulated without benzalkonium chloride?

Yes. A preservative-free nasal product can use unit-dose packaging or an alternative multidose preservation strategy. The formulation must maintain microbial quality, suspension stability, and spray performance.

Is lactose mandatory for inhaled mometasone furoate?

No. Lactose is used in established dry-powder products, but carrier-free particles, mannitol, engineered carbohydrates, and other carrier systems may be technically feasible. Each alternative creates different equivalence and regulatory requirements.

Can a new mometasone cream obtain meaningful patent protection?

Yes, if the claims cover a specific vehicle, release profile, penetration behavior, manufacturing process, or combination of formulation and use. Claims to routine excipient substitutions are less durable.

Is a mometasone furoate foam commercially attractive?

A foam can be attractive for scalp, hairy, and cosmetically sensitive areas where ointments are poorly accepted. Commercial success depends on vehicle feel, application precision, corticosteroid safety, and differentiation from existing generic lotions and creams.

Does a low-global-warming propellant create a new product opportunity?

Yes. A new propellant can support lifecycle management for inhaled mometasone products, but the sponsor must demonstrate comparable dose delivery, aerosol performance, stability, device compatibility, and clinical suitability.

References

1. U.S. Food and Drug Administration. (2023). Nasonex (mometasone furoate monohydrate) nasal spray prescribing information.
2. U.S. Food and Drug Administration. (2023). Asmanex Twisthaler (mometasone furoate) inhalation powder prescribing information.
3. U.S. Food and Drug Administration. (2023). Dulera (mometasone furoate and formoterol fumarate) prescribing information.
4. U.S. Food and Drug Administration. (2023). Elocon (mometasone furoate) cream, ointment, and lotion prescribing information.
5. U.S. Food and Drug Administration. (2023). Product-specific guidance for fluticasone propionate; mometasone furoate inhalation products and related orally inhaled products.
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
7. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.
8. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.